Medicamen Biotech Stock Plummets to New 52-Week Low at Rs.320.25

Medicamen Biotech has reached a new 52-week low, hitting Rs.320.25 on September 26, 2025. This marks a significant decline for the microcap pharmaceutical company, which has seen its stock price fall by 3.62% over the past three days. The stock has consistently underperformed, trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages.
In the broader market context, the Pharmaceuticals & Drugs sector has also experienced a downturn, declining by 2.36%. Medicamen Biotech's performance over the past year has been notably poor, with a return of -40.43%, contrasting sharply with the Sensex's decline of just 5.85% during the same period.

The company's operating profit has decreased at an annual rate of -12.66% over the last five years, and its return on capital employed (ROCE) stands at a low 5.30%. Additionally, cash and cash equivalents have dropped to Rs.3.76 crore, indicating potential liquidity concerns. Despite these challenges, Medicamen Biotech maintains a low debt-to-equity ratio of 0.09, suggesting a conservative approach to leverage.